缬沙坦联合前列地尔对早期糖尿病肾病的临床研究OA北大核心CSCDCSTPCD
Clinical study of valsartan combined with alprostadil in the treatment of patient with early diabetic nephropathy
目的：观察缬沙坦联合前列地尔治疗早期糖尿病肾病的临床疗效及安全性。方法98例早期糖尿病肾病患者分为A组33例，B组31例，C组34例。 A组静脉滴注前列地尔100μg＋0.9％NaCl 250 mL，每日1次；B组口服缬沙坦80 mg，每日1次；C组静脉滴注前列地尔100μg＋0.9％ NaCl 250 mL，口服缬沙坦胶囊80 mg，每日1次，3组疗程均为1个月。比较3组的临床疗效及血清肌酸酐、尿素氮和尿白蛋白排泄率。结果治疗后A、B和C组临床…查看全部>>
Objective To evaluate the clinical efficacy and safety of al-sartan combined with alprostadil in the treatment of early diabetic ne-phropathy.Methods Ninety-eight early diabetic nephropathy patients were divided into three groups , 33 patients in group A , 31 patients in group B , and 34 patients in group C.Patients in group A were given al-prostadil 100 μg +0.9%NaCl 250 mL, qd.Patients in group B were given valsartan 80 mg, qd.And patients in group C were g…查看全部>>
马亚丽;陈芳;时军;陈宝平
河南大学 淮河医院 肾内科，河南 开封475000河南大学 淮河医院 肾内科，河南 开封475000河南大学 淮河医院 肾内科，河南 开封475000河南大学 淮河医院 肾内科，河南 开封475000
临床医学
糖尿病肾病缬沙坦前列地尔尿素氮血清肌酸酐尿白蛋白排泄率
diabetic nephropathyvalsartanalprostadilserumblood urea nitrogen ( BUN )serum creatinine ( Scr )urinary albumin excretion rate ( UAER)
《中国临床药理学杂志》 2016 (5)
409-411,3
河南省卫生厅、河南省医学科技公关计划基金资助项目（2010003089）
评论